# ADCX-020

Source: https://onco.cc/drugs/adcx-020/  
OnCo record `adcx-020` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADCX-020 is an experimental antibody-drug conjugate from Adcytherix, in phase 1 trials for locally advanced or metastatic solid tumours.

## Summary

ADCX-020 is an antibody-drug conjugate from Adcytherix. An antibody-drug conjugate; the company says its ADCs pair clinically validated targets with payloads derived from approved cancer drugs, but has not disclosed ADCX-020's target or payload. Its furthest stage is phase 1, for locally advanced or metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT07238075 recruiting; started 23 February 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ADCX-020
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate; the company says its ADCs pair clinically validated targets with payloads derived from approved cancer drugs, but has not disclosed ADCX-020's target or payload.

## Sources

- Adcytherix: adcytherix.com: https://www.adcytherix.com/
- Adcytherix: adcytherix.com: https://www.adcytherix.com/
- Adcytherix: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07238075
- ClinicalTrials.gov: trials of ADCX-020: https://clinicaltrials.gov/search?intr=ADCX-020

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Adcytherix](https://onco.cc/companies/adcytherix/)
- trials: [ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers](https://onco.cc/trials/nct07238075/)

---
JSON: https://onco.cc/api/v1/entities/adcx-020.json